Improved understanding of renal cell carcinoma (RCC) has led to the recent approval of immuno-oncology therapies (IOs) that can be used in combination with other IOs or with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs). In this interactive webinar experts in RCC discuss IO combinations in RCC, including the rationale for development, clinical trial data, and safety considerations concerning immune-related adverse events. This activity includes interactive polling questions interspersed throughout the activity to engage learners and facilitate application of the clinical concepts presented. Peer responses to the embedded interactive questions are available in real time, enabling learners to reflect on their choices and compare them to those of their colleagues.
